Processa Pharmaceuticals, Inc.
No enriched coverage for $PCSA in the last 7 days.
No SEC Form 4 filings for $PCSA in the last 30 days.
Processa Pharmaceuticals CEO George K. Ng reported an open-market purchase of 1,843 shares of common stock at $2.97 per share, increasing his direct holdings to 3,979 shares. The Form 4/A filing also details indirect holdings through a family trust and an IRRA account. This transaction reflects a net buyer position for Ng, with no insider sales reported in this filing.
Processa Pharmaceuticals' Chief Administrative Officer, Wendy Guy, reported an open-market purchase of 1,748 shares of the company's common stock at $2.69 per share on April 30, 2026. Following this transaction, Guy directly owns 6,441 common shares and indirectly holds 333 additional shares through CorLyst, LLC. This insider filing indicates a neutral sentiment and impact on the company.
Processa Pharmaceuticals, Inc.'s CEO, George K. Ng, reported an open-market purchase of 1,843 shares of common stock at $2.97 per share on April 15, 2026. This transaction increased his direct holdings to 3,979 shares. The filing also disclosed indirect holdings through the Ng Cha Family Trust and a George Ng IRRA account.
